Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial

Diabetes Obes Metab. 2024 Feb;26(2):772-776. doi: 10.1111/dom.15359. Epub 2023 Nov 17.

Authors

Yujuan Fan^{1

2}, Mingfeng Xia¹, Hongmei Yan¹, Xiaoying Li¹, Xinxia Chang¹

Affiliations

¹ Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
² Department of Endocrinology and Metabolism, Minhang Hospital, Fudan University, Shanghai, China.

PMID: 37975640
DOI: 10.1111/dom.15359

No abstract available

Publication types

Randomized Controlled Trial
Letter

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide 1
Humans
Liver
Non-alcoholic Fatty Liver Disease* / complications
Non-alcoholic Fatty Liver Disease* / drug therapy
Peptide Fragments

Substances

glucagon-like peptide 1 (7-36)
Glucagon-Like Peptide 1
Peptide Fragments

Grants and funding

17DZ1910606/Shanghai Science and Technology Fund